文献速递淋巴瘤白血病

泽布替尼对比伊布替尼治疗复发/难治性慢性淋巴细胞白血病及小淋巴细胞淋巴瘤:随机III期试验中期分析

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
PubMed 文献 · J Clin Oncol · 2022-11-17

ALPINE研究为全球随机开放标签III期试验,纳入415例复发/难治性慢性淋巴细胞白血病患者,随机接受泽布替尼(207例)或伊布替尼(208例)。中位随访15个月时,泽布替尼组总缓解率显著高于伊布替尼组(78.3% vs 62.5%,P<.001),12个月无进展生存率更高(94.9% vs 84.0%,HR 0.40),心房颤动发生率更低(2.5% vs 10.1%,P=.001)。

要点

  • 泽布替尼组总缓解率78.3%,显著高于伊布替尼组62.5%(P<.001)。
  • 12个月无进展生存率泽布替尼组94.9% vs 伊布替尼组84.0%(HR 0.40,95%CI 0.23-0.69)。
  • 心房颤动发生率泽布替尼组2.5% vs 伊布替尼组10.1%(P=.001)。

核心结论

  • 泽布替尼相比伊布替尼具有显著更高的总缓解率、更低的心房颤动发生率、更优的无进展生存率和整体心脏安全性。
  • 数据支持选择性BTK抑制可改善疗效/安全性结局。

研究设计与样本

  • ALPINE研究(NCT03734016)为全球、随机、开放标签III期试验,对比泽布替尼与伊布替尼治疗复发/难治性慢性淋巴细胞白血病。
  • 2018年11月1日至2020年12月14日期间共入组652例患者,本次中期分析报告前415例随机分配患者:泽布替尼组207例,伊布替尼组208例。
  • 主要终点为研究者评估的总缓解率;预先计划的中期分析在首批415例患者入组约12个月后进行。

主要发现

  • 中位随访15个月时,总缓解率(部分或完全缓解)泽布替尼组为78.3%(95%CI 72.0-83.7),伊布替尼组为62.5%(95%CI 55.5-69.1),双侧P<.001。
  • 在del(17p)/TP53突变亚组中,总缓解率泽布替尼组80.5% vs 伊布替尼组50.0%;在del(11q)亚组中,泽布替尼组83.6% vs 伊布替尼组69.1%。
  • 所有患者12个月无进展生存率泽布替尼组94.9% vs 伊布替尼组84.0%(风险比0.40;95%CI 0.23-0.69)。
  • 心房颤动发生率泽布替尼组2.5% vs 伊布替尼组10.1%(双侧P=.001)。
  • 泽布替尼组心脏事件、大出血以及导致治疗中断/死亡的不良事件发生率均低于伊布替尼组。

关键数值与推荐

  • 总缓解率(部分或完全缓解):泽布替尼组78.3%(95%CI 72.0-83.7)vs 伊布替尼组62.5%(95%CI 55.5-69.1),双侧P<.001。
  • 12个月无进展生存率:泽布替尼组94.9% vs 伊布替尼组84.0%,风险比0.40(95%CI 0.23-0.69)。
  • 心房颤动发生率:泽布替尼组2.5% vs 伊布替尼组10.1%,双侧P=.001。
  • del(17p)/TP53突变亚组总缓解率:泽布替尼组80.5% vs 伊布替尼组50.0%。
  • del(11q)亚组总缓解率:泽布替尼组83.6% vs 伊布替尼组69.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve efficacy outcomes and increased BTK specificity may minimize off-target inhibition-related toxicities. PATIENTS AND METHODS: ALPINE (ClinicalTrials.gov identifier: NCT03734016) is a global, randomized, open-label phase III study of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The primary end point was investigator-assessed overall response rate (ORR). The preplanned interim analysis was scheduled approximately 12 months after the first 415 patients were enrolled. RESULTS: Between November 1, 2018, and December 14, 2020, 652 patients were enrolled. We present the interim analysis of the first 415 enrolled patients randomly assigned to receive zanubrutinib (n = 207) or ibrutinib (n = 208). At 15 months of median follow-up, ORR (partial or complete response) was significantly higher with zanubrutinib (78.3%; 95% CI, 72.0 to 83.7) versus ibrutinib (62.5%; 95% CI, 55.5 to 69.1; two-sided P < .001). ORR was higher with zanubrutinib versus ibrutinib in subgroups with del(17p)/TP53 mutations (80.5% v 50.0%) and del(11q) (83.6% v 69.1%); 12-month progression-free survival in all patients was higher with zanubrutinib (94.9%) versus ibrutinib (84.0%; hazard ratio, 0.40; 95% CI, 0.23 to 0.69). Atrial fibrillation rate was significantly lower with zanubrutinib versus ibrutinib (2.5% v 10.1%; two-sided P = .001). Rates of cardiac events, major hemorrhages, and adverse events leading to treatment discontinuation/death were lower with zanubrutinib. CONCLUSION: Zanubrutinib had a significantly higher ORR, lower atrial fibrillation rate, and improved progression-free survival and overall cardiac safety profile versus ibrutinib. These data support improved efficacy/safety outcomes with selective BTK inhibition.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. J Clin Oncol. 2022. PMID: 36395435. doi:10.1200/JCO.22.00510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。